Wegovy vs Ozempic: Same Drug, Different Uses [2026]

You have probably heard both names in conversations about weight loss medications. Wegovy and Ozempic are two of the most-prescribed GLP-1 medications in the United States, and they contain the exact same active ingredient: semaglutide. So why do two separate products exist, and does it matter which one you take?

The answer involves FDA regulations, dosing differences, insurance billing, and some important clinical distinctions. This guide explains everything you need to know.

The Basics: Same Molecule, Different Labels

Semaglutide is a GLP-1 receptor agonist — a synthetic version of a gut hormone that regulates appetite, blood sugar, and digestion. Novo Nordisk, the Danish pharmaceutical company that developed semaglutide, markets it under three different brand names:

Brand	Form	FDA Indication	Max Dose
Ozempic	Weekly injection	Type 2 diabetes	2 mg
Wegovy	Weekly injection	Chronic weight management	2.4 mg
Rybelsus	Daily oral tablet	Type 2 diabetes	14 mg
Oral Wegovy	Daily pill	Chronic weight management	Higher-dose oral

The molecule inside the pen is identical. What differs is the approved dose range, the FDA-approved indication (what the drug is officially prescribed for), and how insurance companies categorize the product.

A Brief History of Semaglutide

Understanding how we got here helps make sense of the current landscape:

• 2017: Ozempic receives FDA approval for type 2 diabetes, based on the SUSTAIN clinical trial program
• 2021: Wegovy receives FDA approval for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity, based on the STEP clinical trials
• 2023: The SELECT trial demonstrates Wegovy reduces cardiovascular events by 20% in adults with overweight/obesity
• 2024: Wegovy receives expanded FDA approval to reduce cardiovascular risk
• 2025: Oral Wegovy receives FDA approval for weight management, and Novo Nordisk launches direct-to-consumer pricing
• 2026: Novo Nordisk announces plans to cut list prices by up to 50% starting in 2027

Why the Same Drug Gets Two Names

This is not unusual in pharmaceuticals. Drug companies often seek separate FDA approvals for different conditions because:

1. Different clinical trials are required. Ozempic was tested in diabetes trials (SUSTAIN program). Wegovy was tested in obesity trials (STEP program). Each required its own regulatory submission.
2. Dosing may differ. The optimal dose for blood sugar control (Ozempic, up to 2 mg) is lower than the optimal dose for weight loss (Wegovy, up to 2.4 mg).
3. Insurance formularies treat them differently. A diabetes drug goes through different coverage pathways than a weight management drug.

Dosing: The 0.4 mg Difference That Matters

Both medications follow a gradual dose escalation to minimize side effects, but their schedules differ.

Ozempic Dose Escalation

Weeks	Dose
Weeks 1-4	0.25 mg
Weeks 5-8	0.5 mg
Optional increase	1.0 mg
Maximum dose	2.0 mg

Wegovy Dose Escalation

Weeks	Dose
Weeks 1-4	0.25 mg
Weeks 5-8	0.5 mg
Weeks 9-12	1.0 mg
Weeks 13-16	1.7 mg
Week 17+	2.4 mg (maintenance)

The difference matters. Wegovy's maintenance dose of 2.4 mg is 20% higher than Ozempic's maximum of 2 mg. In the STEP 1 trial (2021), semaglutide 2.4 mg produced 14.9% average body weight loss over 68 weeks. While Ozempic at 2 mg still produces meaningful weight loss (often cited at 10-12% in real-world settings), the extra 0.4 mg in Wegovy translates to additional appetite suppression and weight reduction for many patients.

Additionally, in January 2026, the UK's MHRA approved a higher Wegovy dose of 7.2 mg (administered as three 2.4 mg injections on the same day) for adults with a BMI of 30 or above. This higher dose is currently available only through private providers in the UK and has not yet been approved in the United States.

Weight Loss Results: What the Studies Show

Wegovy (STEP Trials)

Wegovy's FDA approval for weight management was based on the STEP clinical trial program:

• STEP 1 (2021): 14.9% body weight loss over 68 weeks vs 2.4% with placebo in adults without diabetes. 86.4% achieved at least 5% weight loss, and one-third lost 20% or more.
• STEP 3 (2021): Combined with intensive behavioral therapy, 16.0% weight loss over 68 weeks.
• STEP 5 (2022): Long-term data showed 15.2% sustained weight loss over 104 weeks (2 years).
• STEP 8 (2022): In a head-to-head comparison with liraglutide (Saxenda), semaglutide 2.4 mg produced 15.8% weight loss versus 6.4% for liraglutide.

Ozempic (SUSTAIN Trials for Diabetes)

Ozempic's trials focused on blood sugar (A1C) reduction, with weight loss as a secondary outcome:

• SUSTAIN-1 (2017): Semaglutide 1 mg reduced A1C by 1.55% over 30 weeks. Patients also lost an average of 3.7 kg (about 8 lbs).
• SUSTAIN-6 (2016): Demonstrated a 26% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in patients with type 2 diabetes.
• SUSTAIN-7 (2018): Semaglutide 1 mg produced 6.5 kg (14.3 lbs) weight loss compared to 3.0 kg with dulaglutide 1.5 mg over 40 weeks.

While Ozempic was not specifically studied at 2.4 mg for weight loss, many providers prescribe it off-label for weight management, particularly when insurance does not cover Wegovy.

Cardiovascular Benefits: Wegovy's Exclusive Claim

One of the most significant differences between Wegovy and Ozempic in 2026 is Wegovy's cardiovascular indication.

The SELECT Trial (2023) — Wegovy's Game-Changing Moment

The SELECT trial enrolled 17,604 adults aged 45 and older with overweight or obesity plus established cardiovascular disease (but without diabetes). This was one of the largest cardiovascular outcome trials ever conducted for an obesity medication. Key findings:

• Semaglutide 2.4 mg (Wegovy dose) reduced the risk of major adverse cardiovascular events by 20% compared to placebo
• Specifically: fewer heart attacks, strokes, and cardiovascular deaths
• The cardiovascular benefit appeared within the first 6-12 months of treatment
• Benefits were observed regardless of baseline BMI or amount of weight lost — suggesting the cardiovascular protection goes beyond weight loss alone
• Mean weight loss in SELECT was 9.4%, confirming that even moderate weight loss with semaglutide carries heart protection

Based on SELECT, in March 2024, Wegovy became the first FDA-approved obesity medication with an indication to reduce cardiovascular risk. This is a label that Ozempic does not carry for the obesity population, even though it uses the same active ingredient.

This distinction matters enormously for three reasons:

1. Insurance coverage: Some insurers that previously denied coverage for weight loss medications now cover Wegovy when prescribed to reduce cardiovascular risk in eligible patients
2. Medical necessity arguments: The cardiovascular indication provides stronger clinical justification for prior authorization appeals
3. Clinical positioning: For patients with obesity and existing heart disease, Wegovy is no longer "just" a weight loss drug — it is a cardiovascular risk reduction therapy

Ozempic's Cardiovascular Data (SUSTAIN-6)

Ozempic is not without cardiovascular evidence. The SUSTAIN-6 trial (2016) showed semaglutide 1 mg reduced major adverse cardiovascular events by 26% in patients with type 2 diabetes. However, this trial used a lower dose (1 mg vs 2.4 mg in SELECT), enrolled patients with diabetes (not obesity without diabetes), and had a smaller sample size. It led to a cardiovascular benefit indication for Ozempic, but specifically in the diabetes population — a different clinical context than weight management.

Side Effects: Essentially Identical

Because both products contain semaglutide, their side effect profiles are virtually the same. The most common adverse effects are gastrointestinal:

• Nausea: 44% of patients (most common, usually improves over time)
• Diarrhea: 30% of patients
• Vomiting: 21% of patients
• Constipation: 29% of patients
• Abdominal pain: 10-15% of patients
• Headache: 10-14% of patients
• Fatigue: 5-10% of patients (often improves as diet adjusts)
• Dizziness: 5-7% of patients

Side effects are typically mild to moderate and most frequent during dose escalation. They tend to improve significantly by weeks 8-12 as your body adjusts. In the STEP 1 trial, only 7% of semaglutide patients discontinued treatment due to adverse events, meaning 93% found the side effects manageable enough to continue.

Serious Side Effects (Rare for Both)

Both Wegovy and Ozempic carry the same boxed warnings and serious adverse event profile:

• Pancreatitis: Inflammation of the pancreas, characterized by severe, persistent abdominal pain that may radiate to the back. Incidence is less than 1% but requires immediate medical attention. Patients with a history of pancreatitis should not take semaglutide.
• Gallbladder disease: Gallstones and gallbladder inflammation (cholecystitis) are more common with rapid weight loss. In STEP 1, gallbladder-related events occurred in 2.6% of semaglutide patients vs 1.2% with placebo. Symptoms include severe upper-right abdominal pain, especially after fatty meals.
• Thyroid C-cell tumors: A boxed warning based on rodent studies showing increased thyroid tumors. This has not been confirmed in humans, but semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
• Acute kidney injury: Typically caused by dehydration from severe vomiting or diarrhea. Patients should stay well-hydrated and report persistent GI symptoms to their provider.
• Hypoglycemia: Rare when semaglutide is used alone, but risk increases when combined with insulin or sulfonylureas for diabetes management.

Managing Side Effects During Dose Escalation

Practical tips for minimizing discomfort:

• Eat smaller meals throughout the day rather than three large ones
• Avoid greasy, fried, or very sweet foods, especially during dose increases
• Take your injection at the same time each week — some patients find evening injections reduce next-day nausea
• Drink at least 64 ounces of water daily to prevent dehydration and constipation
• If nausea is severe, ask your doctor about temporarily staying at the current dose for an extra week before increasing
• Ginger tea, ginger chews, or prescription ondansetron can help manage acute nausea episodes

Because Wegovy's maintenance dose is slightly higher (2.4 mg vs 2 mg), some patients may experience marginally more intense GI side effects at the top dose, though clinical trials have not shown a statistically significant difference in overall adverse event rates between the two dose levels.

Hair Loss: A Common Concern

Many patients report temporary hair thinning during GLP-1 therapy. It is important to understand this is caused by rapid weight loss (telogen effluvium), not the medication itself. Any significant calorie restriction that causes rapid weight loss — whether from medication, surgery, or dieting — can trigger temporary hair shedding. In the STEP 1 trial, alopecia was reported in 3% of semaglutide patients vs 1% with placebo. The hair typically regrows once weight stabilizes, and adequate protein intake helps minimize the effect.

Muscle Loss: The Underappreciated Risk

Weight loss from any method includes both fat loss and lean muscle loss. In clinical trials, approximately 25-40% of total weight lost was lean mass (including muscle). This is one of the most important reasons to combine GLP-1 therapy with:

• Resistance training 2-3 times per week
• Adequate protein intake (0.7-1.0 grams per pound of goal body weight daily)
• Proper nutrition from the reduced calories you do consume

This applies equally to both Wegovy and Ozempic. The medication suppresses appetite, which is its job — but ensuring you eat enough protein and exercise regularly is your job to preserve metabolic health.

Cost and Pricing: 2026 Landscape

List Prices

Medication	Monthly List Price
Wegovy	$1,349/month
Ozempic	$1,028/month
Rybelsus	$1,028/month

Novo Nordisk Self-Pay Program (2025-2026)

Novo Nordisk made significant pricing moves in late 2025 and early 2026:

• Standard self-pay price: $349/month for both Wegovy (injection) and Ozempic
• Introductory offer: $199/month for the first 2 months (new self-pay patients, through March 31, 2026)
• Oral Wegovy (pill): $149-$299/month depending on dose
• Costco cash pricing: $499/month for both Wegovy and Ozempic

Additionally, Novo Nordisk announced in February 2026 that it will cut list prices by up to 50% starting in 2027, which would bring the list price of Wegovy below $700/month.

With Insurance

• Commercial plans with coverage: Copays as low as $25-$50/month with manufacturer savings cards
• Plans without weight loss drug coverage: Ozempic may be covered as a diabetes medication even when Wegovy is denied for weight loss
• Medicare: Currently does not cover GLP-1 for weight loss, but the BALANCE demonstration model launching April 2026 will cover eligible beneficiaries at $50/month copay

The Off-Label Ozempic Dilemma

One of the most common scenarios in GLP-1 prescribing involves Ozempic being used off-label for weight loss. Here is why this happens and what you should know.

Why Doctors Prescribe Ozempic for Weight Loss

• Insurance covers Ozempic for diabetes but denies Wegovy for weight management
• Many patients with obesity also have prediabetes or metabolic syndrome, making Ozempic a clinically defensible choice
• The medications are pharmacologically identical, just at different dose levels

The Limitations of Off-Label Use

• Ozempic's maximum dose is 2 mg, not the 2.4 mg used in STEP weight loss trials
• If using Ozempic off-label for weight loss, you may not qualify for the cardiovascular indication
• Insurance audits may flag off-label prescribing patterns
• You may not achieve the same weight loss as the STEP trial results (which used 2.4 mg)

What to Ask Your Doctor

If your insurance denies Wegovy but covers Ozempic, ask your provider:

1. Do I have any comorbidities (prediabetes, metabolic syndrome) that would make Ozempic appropriate?
2. Would Ozempic at 2 mg produce meaningful weight loss for my situation?
3. Can we appeal the Wegovy denial with documentation of medical necessity?
4. Should I consider Novo Nordisk's self-pay program at $349/month for Wegovy instead?

The Prior Authorization Process

For patients navigating insurance denials, understanding the prior authorization process is essential:

1. Your doctor submits clinical documentation — typically BMI, weight history, failed dietary/exercise interventions, and relevant comorbidities
2. The insurer reviews — usually within 5-15 business days
3. If approved — your prescription is filled at your plan's copay level
4. If denied — you have the right to appeal. First-level appeals often involve additional documentation from your doctor (a letter of medical necessity citing clinical guidelines). Second-level appeals may involve peer-to-peer review where your doctor speaks directly with the insurer's medical director.
5. External review — if internal appeals fail, most states allow you to request an independent external review

Success tips for appeals:

• Reference the American Medical Association's recognition of obesity as a chronic disease
• Cite the relevant clinical trial data (STEP trials for Wegovy, SUSTAIN trials for Ozempic)
• For Wegovy specifically, cite the SELECT trial cardiovascular benefit if you have any cardiovascular risk factors
• Document all lifestyle interventions you have tried (diet programs, exercise regimens, behavioral counseling)
• Include a detailed medical history showing weight-related comorbidities

Oral Semaglutide: The Pill Option

If needles are a barrier, oral semaglutide may be an alternative.

Rybelsus (Currently Available)

Rybelsus is a daily oral tablet approved for type 2 diabetes at doses up to 14 mg. It provides blood sugar benefits but produces less weight loss than the injectable forms because oral bioavailability of semaglutide is much lower — only about 1% of the oral dose is absorbed.

Oral Wegovy (Approved 2025)

In 2025, the FDA approved an oral formulation of Wegovy for weight management. This is a higher-dose oral semaglutide specifically formulated for weight loss. Key details:

• Taken once daily as a pill
• Priced at $149-$299/month through Novo Nordisk's direct-to-consumer channel depending on dose
• Eliminates the need for weekly injections
• Early data suggests weight loss results comparable to, though potentially slightly less than, the injectable form

The oral formulation uses a special absorption enhancer (SNAC) that helps semaglutide survive the stomach's acidic environment and pass through the stomach lining into the bloodstream. However, oral bioavailability remains low (around 1%), which is why the oral dose is measured in milligrams while the injectable dose is measured in fractions of a milligram — much more of the drug is needed orally to achieve similar blood levels.

Practical Considerations for Oral Semaglutide

Taking oral semaglutide requires a specific routine that some patients find inconvenient:

• Must be taken on an empty stomach with no more than 4 ounces (half a glass) of plain water
• Wait at least 30 minutes before eating, drinking anything else, or taking other oral medications
• Take at the same time each day for consistent absorption
• Do not crush, chew, or split the tablet — it must be swallowed whole

Some patients find this daily routine more burdensome than a single weekly injection. Others strongly prefer taking a pill to using a needle. It comes down to personal preference and lifestyle compatibility.

For patients who travel frequently, the oral formulation has a practical advantage: no need for cold storage (injectable semaglutide pens should be refrigerated before first use) and no carrying needles through airport security.

Real-World Considerations: Supply, Availability, and Shortages

The practical reality of getting GLP-1 medications has been a significant challenge over the past few years, and it is worth understanding how supply issues have affected Wegovy and Ozempic differently.

The Shortage Timeline

• 2022-2023: Both Wegovy and Ozempic experienced severe supply shortages as demand exploded. Wegovy was particularly hard to find, with some patients unable to fill prescriptions for months.
• 2024: Supply improved but remained tight. Certain dose strengths (especially Wegovy's starter doses of 0.25 mg and 0.5 mg) were intermittently unavailable.
• 2025-2026: Novo Nordisk invested billions in manufacturing expansion, including new production facilities in Denmark and North Carolina. Supply has stabilized significantly, though sporadic regional shortages still occur.

How Shortages Affected the Market

The shortages had several ripple effects:

• Many patients were started on Ozempic off-label for weight loss because it was more readily available than Wegovy
• Compounding pharmacies entered the market to fill the gap, creating the compounded semaglutide industry
• Some patients switched to tirzepatide (Mounjaro/Zepbound) because of semaglutide supply issues, even if semaglutide was their first choice
• Telehealth platforms that could source compounded semaglutide grew rapidly

Current Supply Status (March 2026)

As of early 2026, both Wegovy and Ozempic are generally available at most pharmacies. Novo Nordisk's manufacturing expansion has largely resolved the supply crisis. The company invested over $6 billion in new manufacturing facilities, including a major plant in Clayton, North Carolina, and expanded capacity at its existing facilities in Denmark. However, it is still worth checking availability at your pharmacy before starting treatment, and having a backup pharmacy identified in case of localized shortages.

If you encounter a shortage at your pharmacy, these steps can help:

• Ask your pharmacist to check availability at nearby locations in the same chain
• Contact Novo Nordisk's patient support line at NovoCare for help locating supply
• Consider mail-order pharmacy options, which often have better stock than retail locations
• Ask your doctor whether temporarily switching to a different semaglutide formulation (e.g., oral instead of injectable) is appropriate while supply normalizes

How to Decide: Wegovy vs Ozempic

Choose Wegovy If:

• Your primary goal is weight management and your BMI qualifies (30+ or 27+ with comorbidities)
• You want the FDA-approved cardiovascular benefit for obesity
• Your insurance covers Wegovy or you can afford the $349/month self-pay price
• You want to achieve the maximum possible dose (2.4 mg) studied in weight loss trials
• You prefer the weight management-specific dosing schedule

Choose Ozempic If:

• You have type 2 diabetes (with or without weight loss goals)
• Your insurance covers Ozempic but not Wegovy
• Your doctor determines the 2 mg maximum dose is sufficient for your needs
• You are already on Ozempic for diabetes and want to continue the same medication
• Cost is a primary concern and Ozempic has better coverage through your plan

Consider Oral Semaglutide If:

• You have a strong needle phobia or preference against injections
• You want a lower-cost entry point ($149-$299/month)
• You are comfortable with daily dosing rather than weekly
• You understand the potential trade-off in efficacy compared to injectable forms

Frequently Asked Questions

Can my doctor switch me from Ozempic to Wegovy?

Yes, switching from Ozempic to Wegovy is straightforward since both contain semaglutide. Your doctor will typically transition you directly to the equivalent or next-higher Wegovy dose without restarting the full escalation schedule. For example, if you are on Ozempic 1 mg, you might start Wegovy at the 1.0 mg or 1.7 mg dose. No washout period is needed because you are staying on the same molecule.

Is it safe to use Ozempic off-label for weight loss?

Ozempic is widely used off-label for weight loss, and since it contains the same semaglutide as Wegovy, the safety profile is well-established. However, off-label use means you may not reach the 2.4 mg dose studied in the STEP weight loss trials. Your doctor can determine if Ozempic at up to 2 mg is appropriate for your weight management goals based on your individual health profile.

Will my insurance cover Wegovy for weight loss?

Coverage has expanded significantly since 2023, but it varies by plan. Most large commercial insurers now include at least one GLP-1 for weight management on their formularies, though prior authorization is almost always required. You will typically need documentation of BMI, failed lifestyle interventions, and relevant comorbidities. If Wegovy is denied, your doctor may be able to prescribe Ozempic if you have qualifying metabolic conditions.

How much weight can I expect to lose on Wegovy vs Ozempic?

In clinical trials, Wegovy at 2.4 mg produced average weight loss of 14.9% over 68 weeks (STEP 1, 2021). Ozempic has not been studied at equivalent doses specifically for weight loss, but real-world data suggests Ozempic users typically lose 10-12% of body weight. The 2-4% difference is largely attributed to Wegovy's higher maximum dose. Individual results vary significantly based on starting weight, diet, exercise, and metabolic factors.

Are there any advantages to taking the oral semaglutide pill over injections?

The main advantage is convenience — no needles, no refrigeration requirements, and daily dosing that some patients find easier to remember than weekly injections. The oral Wegovy pill (FDA-approved December 2025, widely available January 2026) offers a lower-cost entry point at $149/month for the starting dose and $299/month for the highest dose. However, oral semaglutide has lower bioavailability than the injectable form, and you must take it on an empty stomach with a small sip of water, then wait 30 minutes before eating or taking other medications. Some patients find this daily routine more burdensome than a once-weekly injection.

Talking to Your Doctor: Questions to Ask

Going into your appointment prepared will help you get the most out of the conversation and leave with a clear plan. Here are the key questions to raise:

About Your Eligibility

• "Based on my BMI and health history, do I qualify for semaglutide? Which product — Wegovy or Ozempic — makes the most sense for my situation?"
• "Do I have any conditions (prediabetes, metabolic syndrome, cardiovascular risk factors) that would affect which product we choose?"
• "Are there any reasons semaglutide might not be safe for me?" (Important if you have a history of pancreatitis, thyroid cancer, or MEN2 syndrome)

About Insurance and Cost

• "Which semaglutide product does my insurance formulary cover?"
• "If my plan denies Wegovy, can we pursue a prior authorization appeal? What documentation would strengthen the case?"
• "Should I consider the Novo Nordisk self-pay program at $349/month versus going through insurance?"
• "Do I qualify for any patient assistance programs?"

About Long-Term Planning

• "How long should I expect to take this medication?"
• "What monitoring and lab work will I need while on semaglutide?"
• "What happens if the medication stops working or I plateau?"
• "Is there a plan for preserving muscle mass during weight loss — should I see a dietitian or work with a trainer?"

About Side Effects

• "What should I do if nausea becomes severe during dose escalation?"
• "Are there foods or habits I should change before starting to minimize side effects?"
• "At what point should I contact you about side effects versus managing them at home?"

Final Takeaway

Wegovy and Ozempic are the same drug wearing different labels. The differences come down to dose (Wegovy goes higher at 2.4 mg), approved use (weight management vs diabetes), cardiovascular indication (Wegovy only, based on SELECT trial data), and insurance coverage (which varies significantly by plan).

For weight loss specifically, Wegovy at 2.4 mg has the stronger clinical evidence behind it — 14.9% average body weight loss in STEP 1, plus a proven 20% reduction in cardiovascular events in SELECT. But if cost or insurance makes Ozempic the more practical choice, it is still an effective option — the difference in maximum dose (2.0 mg vs 2.4 mg) is meaningful but not dramatic, and real-world data shows Ozempic users still achieve 10-12% weight loss on average.

Here is a quick decision framework:

• Heart disease risk + weight loss goal? Wegovy is the clear choice for its cardiovascular indication.
• Type 2 diabetes + weight loss goal? Ozempic addresses both, and your insurer is more likely to cover it.
• Needle-averse? Oral Wegovy gives you a pill option at $149-$299/month.
• Cost is the primary barrier? Compare your insurance copay for each product, then check the $349/month self-pay option.
• Already on Ozempic and happy? There may not be a compelling reason to switch, unless you want the cardiovascular indication or the higher 2.4 mg dose.

The most important step is talking to your healthcare provider about which product fits your health profile, insurance situation, and long-term treatment plan. Whether you end up on Wegovy, Ozempic, or the new oral formulation, the semaglutide molecule inside is the same proven medication that has helped millions of people achieve clinically significant weight loss.

This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any medication.

Affiliate disclosure: The GLP-1 Daily may earn a commission from links in this article. This does not affect our editorial independence or the accuracy of our content.

Related Reading

• Wegovy Users Face 5x Higher Risk of Sudden Vision Loss Than Ozempic Users, Study Finds
• Wegovy Pill vs. Wegovy Injection: What Changed in 2026
• Ozempic Face: Why It Happens and Exactly How to Prevent It

-- The GLP-1 Daily Team